On June 8, the Hong Kong Stock Exchange (HKEX) website showed that the IPO application submitted by HighLight Pharmaceutical has been accepted. The joint sponsors for this IPO are CICC and CMB International. Founded in 2017 and headquartered in Hangzhou,…
Nuvalent has been announced to be acquired by GlaxoSmithKline (GSK) on June 9 for $10.6 billion, with an anticipated purchase price of $124 per share, representing a 40% premium over the recent closing price. Nuvalent is a Boston-based clinical-stage biopharmaceutical…
MIL62 (generic name: Obinutuzumab β Injection) has been granted clinical development and commercialization rights in the Asia-Pacific region (including Southeast Asia, India, South Korea, Australia, New Zealand, as well as Hong Kong (China), Macau (China), and Taiwan (China)) under a…
registration, and commercialization in multiple countries and regions across the Asia-Pacific, including Southeast Asia, South Korea, Australia, as well as Hong Kong (China), Macau (China), and Taiwan (China). Vicagrel has been granted exclusive rights for clinical development, registration, and commercialization…
On June 9, Zai Lab announced that its ADC novel drug Tisotumab Vedotin has received its first marketing approval in China for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed during or after chemotherapy.…
Recently, the results of the pivotal ERUPTE Phase II clinical trial, led by Professor Jing Zhicheng from Guangdong Provincial People’s Hospital, were officially published in Med, a Cell Press journal. This study represents a breakthrough in the global development of novel…
On June 8, the NMPA official website showed that Remegen’s Telitacicept (brand name: Tai’ai®) has been approved for two new indications: 1) for the treatment of adult patients with primary immunoglobulin A (IgA) nephropathy at risk of disease progression to significantly…
On June 8, the NMPA official website showed that Teva Pharmaceuticals’ Fremanezumab Injection has been approved for marketing in China. Based on public information and clinical trial progress, the Insight database speculates that the approved indication is for the preventive treatment…
Bexobrutideg (NX-5948), a BTK degrader, is the subject of an exclusive licensing agreement announced on June 8 between Roche and Nurix Therapeutics to co-develop the drug in a deal totaling up to $2.3 billion. The collaboration covers clinical development programs…
On June 8, Zenshine Pharmaceutical issued a press release announcing that a new indication for its Category 1 anti-influenza novel drug Maxeloxaban Tablets (brand name: Jikeshu®) has been approved by the NMPA for the treatment of influenza in adolescents. Previously, in…